Patent ID: 7842661
Filing Date: 2010-11-30
Classification: A61K,C07K

Abstract:
1. A pharmaceutical composition comprising about 0.1 mg/ml to about 1 mg/ml of an erythropoietin peptide and a buffer, the composition having a pH from 5.5 to 6.5, wherein the erythropoietin peptide comprises a glycosyl linking group attached to an amino acid residue or a glycosyl residue of said peptide, wherein the amino acid residue is selected from the group consisting of serine, threonine, and asparagine, said glycosyl linking group comprising a modified sialyl residue having the formula: wherein R wherein R wherein s is an integer from 1 to 20; f is an integer from 1 to 2500; and Q is a member selected from H and substituted or unsubstituted C wherein the buffer comprises one or more members selected from the group consisting of acetate, carbonate, citrate, glycinate, histidine, lactate, maleate, phosphate, succinate, tartrate, and tris; and the pharmaceutical composition shows no detectable level of aggregation of the erythropoietin peptide as measured by SEC-HPLC after three months at a temperature of 5° C. or lower.